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Summary Non-progression and duration of preclinical neoplastic lesions of the cervix uteri were studied using screening data from a
previously unscreened population, Maribo County, Denmark (1966-82). To estimate regression rates, the incidence of clinical cancer before
the screening programme was related to the prevalence and incidence of preclinical lesions estimated from the detection rates of first smear
and third and subsequent smears respectively. Duration was estimated from the time lag between the cumulative incidence of preclinical
lesions and the combined cumulative incidence of clinical cancer and the estimated 'incidence of regression'. Of all preclinical lesions in
women aged 25-50, 24% progressed, 39% regressed and 38% remained. Even if we assume no onset of preclinical lesions above age 50,
we estimated that 48% of the preclinical lesions would not progress to clinical cancer in the women's lifetime. The estimated mean duration of
preclinical lesions was 16 years. In Maribo County during the 1970s, the positive rate (1.6%) was low compared with current rates in several
countries. We conclude that the detection of non-progressive lesions was outweighed by the prevention of clinical cancer.
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A thorough understanding of the natural history of a disease is
among the basic requirements for the initiation and evaluation of
screening programmes (Wilson and Jungner, 1968). However, the
natural history ofcervical cancer can only be learned directly from
the experience of women with positive smears followed without
treatment until development ofinvasive cervical cancer. As obser-
vation without treatment has been considered unethical for many
years, such data on the natural history ofcervical cancer are avail-
able only for small groups of women (Ostor, 1993). Nevertheless,
data from the first and subsequent rounds of mass screening in a
previously unscreened population can give insight into crucial
aspects of screening for cervical cancer, such as regression and
duration ofthe preclinical stage (Boyes et al, 1982).
Maribo County in Denmark is an area in which cervical smears
were not used before an organized screening programme was
started in 1967 for all women aged 30-49 years (Berget, 1979).
From the beginning, the local pathologists ensured registration of
all smears and cervical biopsies taken in the area (Lynge and Poll,
1986a,b). This combination of screening started from scratch and
complete registration makes Maribo County an ideal setting for
the study ofthe natural history ofcervical cancer.
We analysed the data ofMaribo County focusing on the estima-
tion of non-progression rates and duration ofthe preclinical stage.
Estimates were obtained by relating detection rates among first
smears ('prevalence of preclinical lesions') and detection rates of
repeated smears ('incidence of preclinical lesions') to the inci-
dence of clinical cancer in the unscreened population. Non-
progression contributes to the negative side-effects of screening.
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Duration ofthe preclinical lesion is an important parameter in rela-
tion to the time interval in screening programmes.
MATERIALS AND METHODS
Screening data of Maribo County
In the Maribo County screening programme, women aged 30-49
were invited for an examination every fourth year. In the analysis,
we included data from August 1966, when the pathology depart-
ment began operation, until December 1982, when the fourth
round of the screening programme ended. For the women in the
cohort, data on cervical smears and biopsies (Maribo County
pathology department), data on surgery involving the cervix uteri
(Maribo County hospitals) and data on invasive cervical cancer,
migration and death (national data) had previously been merged
into one register (Lynge and Poll, 1986a,b). Data for the present
study were retrieved from this merged register.
In the database smears were registered either as 'primary
smears' or as 'follow-up smears'. Primary smears were taken
within Maribo County by general practitioners, either following an
invitation from the organized screening programme or outside the
organized programme. A total of 109 278 primary smears were
registered in Maribo County during the study period. Smears were
classified as: unqualified, negative, atypical cells, cells slightly
suspicious for malignancy, cells moderately suspicious for malig-
nancy or cells highly suspicious for malignancy. An unqualified
smear was followed by a new smear and, in the present analysis,
the smear taken directly after an unqualified smear is used as the
primary smear. Patients with at least atypical cells were followed
up mostly with a biopsy, which was classified as normal, light
dysplasia [cervical intraepithelial neoplasia (CIN) I], moderate
dysplasia (CIN II), severe dysplasia or carcinoma in situ (CIN III)
or invasive cervical cancer.
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We considered all 99 022 primary smears (consisting of 28 403
first smears, 22 869 second smears and 47 750 third and subse-
quent smears) without any history ofcervical abnormality. Smears
in women with a previous positive smear, biopsy or a surgical
intervention (hysterectomy, collum amputation, conization, elec-
trocauterization or cryotherapy) have been excluded. To avoid
cases in which symptoms had led to the primary smear, we
excluded smears with a biopsy registered within 4 days after the
smear. These biopsies were most probably taken on the same day
as the smears or at least they were not taken as a result ofthe smear.
The follow-up after a smear with at least atypical cells [in the
following referred to as positive smear (1595 cases)] was summa-
rized into one diagnosis, the highest diagnosis. If the histological
follow-up was negative, or if there was no histology and all
follow-up smears were negative, the case was considered to have a
negative diagnosis. Smears with at least CIN I as the maximum
histological follow-up diagnosis were considered to be positive
cases. As symptomatic women were excluded, all positive cases
were considered to be preclinical lesions. These included
dysplasia, carcinoma in situ and preclinical invasive lesions.
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Figure 1 Relation between prevalence of preclinical lesions (P, and F2),
cumulative incidence of preclinical lesions (/d) and cumulative incidence of
clinical cancer (Ia) in (A) a situation without regression (P1 + /d= P2 + /c)~(B) a
situation with regression and (C) for the duration of the preclinical lesion. X
represents all 'missing' cases.-, Preclinical incidence;-, clinical incidence;
---,Ano longer preinvasive
Estimation of non-progression rates
If no regression occurs all preclinical lesions stay as such or
progress to clinical invasive cancer. The sum of the prevalence
(P,) ofpreclinical lesions in unscreened women at age a,, plus the
incidence (Id) ofpreclinical lesions during the age interval a1 to a2
is equal to the prevalence (P2) ofpreclinical lesions in unscreened
women at age a2 plus the incidence ofclinical cancer(Ic) of inva-
sive cancer in the situation without screening, during the age
interval a1 to a2: PI +Id = P2 + Ic (Figure IA). Ifregression occurs,
part ofthe preclinical lesions present at a1 or developed during the
interval (Id) are no longer present at a2 as preclinical stage (P2) or
as invasive cancer (IC). The part of preclinical lesions 'missing' at
a2 (X) is equal to (P, + Id) - (P2 +IC) (Figure IB).
The proportion of lesions that regressed during the interval
('interval regression') was estimated by the number of 'missing
lesions' divided by all preclinical lesions known between a, up to
a2: [(P, + Id) - (P2 + IC)]/(PI + Id). The 'interval progression' was
estimated by the number of progressed lesions divided by all
preclinical lesions in the interval: IA/(P, + Id). The proportion of
lesions that are still prevalent at a2 was calculated by the rate of
prevalent lesions at a2 divided by all preclinical lesions: P21(PI +Id)
The interval regression, interval progression and lesions which
stay prevalent were estimated for the age interval 25-50. The
prevalences P1 and P2 at age 25 and age 50, respectively, and the
incidence Id were estimated from the screening results. The cumu-
lative incidence IC was estimated from the cumulative incidence
over the age interval 25-50 ofclinical cancer.
The age interval 25-50 years was used because of the small
number of screen-detected cases in younger and older women. An
estimate for the progression oflesions still prevalent at age 50 was
obtained by dividing the cumulative incidence IC from age 50 to
age 80 by the prevalence P2 at age 50. The derived estimate of
non-progression in women over 50 years of age, which is given by
(l-Ic/P2) was combined with the above estimated interval regres-
sion, in women between 25 and 50 years of age, to calculate the
non-progression for women over 25 years of age.
Confidence intervals for interval regression, interval progression,
proportion prevalent lesions and minimal non-progression were
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Table 1 Histological follow-up by cytological result of all positive primary smears, Maribo County 1966-82
Cytology of primary smear All smears Smears without sufficient follow-up Smears with sufficient follow-up
No preclinical lesion Preclinical lesion
Cases Percentage Cases Percentage
Atypical 326 97 171 75 58 25
Light suspect 628 28 222 37 378 63
Moderate suspect 498 7 82 17 409 83
Severe suspect 143 5 16 12 122 88
All 1595 137 491 33 977 67
estimated using approximate interval estimation techniques for rate
ratios adapted for this particular situation (Kleinbaum et al, 1982).
Prevalence ofpreclinical lesions: P1 andP2
Detection rates of the first smear were calculated for ages 20, 25,
30, 35, 40, 45, 50, 55 and 60 as theproportion ofpositive smears in
the interval [age - 2.5 to age + 2.5]. The prevalence ofpreclinical
lesions in unscreened women was estimated by correcting the
detection rates for false-negative test results, assuming a sensi-
tivity of 80% (Oortmarssen and Habbema, 1991). For comparison
we also used sensitivities of70% and 90%.
Incidence ofpreclinical lesions during the age intervala
to a2:Id
The incidence ofpreclinical lesions was estimated from the detec-
tion rates at the third and subsequent smears. We excluded the
second smear due to thebias causedby detection offalse negatives
from the first smear. We estimated the age at onset of preclinical
lesions as the age halfway between the last negative smear and the
first positive smear (age at midpoint). We calculated the corre-
sponding incidence rate per woman-year at risk for the third
and subsequent smears. For example, a woman with a negative
smear at age 23 and a positive smear at age 31 (age at midpoint =
27) will contribute 2 woman-years to the age group 20-24 in
Table 2 Detection rates of the first smear and estimation of prevalence of
preclinical cervical lesions in Maribo County, 1966-82
Agea Number of Number of Detection rate Estimated
positive casesb smears (x 10 3 smears) prevalencec
(x 10 3 women)
20 3.0 1382 2.2 2.7
25 33.3 4059 8.2 10.3
30 174.3 7523 23.2 29.0
35 141.5 4470 31.7 39.6
40 129.7 4006 32.4 40.5
45 106.7 3570 29.9 37.3
50 60.9 2986 20.4 25.5
55 3.0 307 9.8 12.2
60 1.0 85 11.4 14.2
60+ 0.0 15 0.0 0.0
20+ 653.4 28403 23.0 28.8
aThe prevalence is estimated for the age a, by mean of [a - 2.5, a + 2.5].
bFirst smears without sufficient follow-up have been redistributed based on
their cytology of the primary smear (see Table 1).
cAssuming an 80% sensitivity.
the denominator. For the age group 25-29 it will result in one
positive diagnosis in the numerator and 2 woman-years in the
denominator. In case both smears were negative this woman
would contribute 2 woman-years to the age group 20-24, 5
woman-years to the age range 25-29 and 1 woman-year to the
age group 30-34 in the denominators. Cumulated incidence rates
(Id) were calculated by adding the incidence rates from each of
the 5-year age groups andmultiplyingby 5.
Incidence ofclinical cancerduring the age intervalal to a2
given noscreening:Ic
Incidence rates for Maribo County are available from 1958 to
1962, the period just before screening started. The age-specific
incidence rates for all of Denmark from 1958 to 1962 (Doll et al,
1966) did not differ significantly from those of Maribo County.
The Maribo County rates show an irregular age trend because of
the relatively small numbers; in the analysis we therefore used the
national incidence rates. This incidence of clinical cancer is
corrected for women not at risk (without acervix uteri), using age-
specific hysterectomy data from Mamibo County.
Estimation of preclinical duration
Preclinical lesions will stay prevalent for some time after which
they will regress to normal or progress to clinical invasive cancer.
The time they will remain screen-detectable is known as the
preclinical duration. As canbe seen fromFigure 1C the cumulative
incidence of Ie up to a certain age of lesions that are no longer
prevalentbecause ofprogression (I') orregression (X), can be esti-
mated by subtracting the prevalence at that age from the cumula-
tive incidence of preclinical lesions up to this age, I = Id- P. A
rough estimate of the preclinical duration is then the number of
years between the age where Id reaches a certain level and the age
where Ie reaches the same level.
It is assumed that the duration of the preclinical stage is
described by a Weibull probability distribution F(x;m,b) with two
parameters: mean duration m and shape (or concentration para-
meter) b (Oortmarssen and Habbema, 1991). For a given Weibull
distribution the expected cumulative rate of lesions that have
regressed or progressed can then be calculated for each 5-year
age group i:
I* = Ij F(QT - a.)
where 7ak is the age at midpoint of a given 5-year age group k, Idk
the incidence ofpreclinical lesions in the age groupj, and F(x) the
Weibull distribution of the duration of the preclinical stage. The
best-fitting parameters m and b are obtained by minimizing the
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Table 3 Estimation of incidence and cumulative incidence of preclinical
cervical lesions by age, based on detection rates of the third and subsequent
smears, in Maribo County, 1966-82
Age Number Number of Incidence Cumulative
of positive women- of preclinical incidence of
casesa years lesions preclinical
(x 10 3 years) lesions
(x 103 years)
<20 0.0 43 0 0
20-25 2.6 1890 1.37 6.9
25-30 56.5 10698 5.28 33.3
30-35 51.8 20377 2.54 46.0
35-40 34.5 23550 1.47 53.3
40-45 24.7 19615 1.26 59.6
45-50 17.5 17752 0.99 64.5
50-55 13.2 8950 1.47 71.9
55-60 0.7 3396 0.21 72.9
60+ 0.0 388 0 72.9
All ages 201.5 106228 1.90
aThird and subsequent smears without sufficient follow-up have been
redistributed based on their cytology of the primary smear (see Table 1).
difference between the observed (Ie) and the expected (I*) cumula-
tive incidence oflesions that have regressed or progressed.
RESULTS
Insufficient follow-up and predictive values
During the study period 1595 women had apositiveprimary smear
in Maribo County: 61% of these had a histologically confirmed
preclinical lesion, 31% no preclinical lesions and 9% were insuffi-
ciently followed up. For cases with sufficient follow-up, the posi-
tive predictive value ofa positive smear (atypia +) for at least CIN
was 67%. This value varied with the cytology of the primary
smear, from 25% for 'atypical cells' to 88% for 'cells highly
suspected for malignancy' (Table 1).
Incidence and prevalence
The detection rates ofpreclinical lesions atthe first smear are shown
in Table 2. The prevalence of preclinical lesions in unscreened
women, derived from these detection rates by correcting for an
assumed 80% sensitivity, was 2.9% in women over 20 years ofage.
The highest prevalence (4%) was found at age 40.
The incidence of preclinical lesions is estimated by the detec-
tion rates per 1000 woman-years of the third and subsequent
smears (Table 3), and shows a peak in age group 25-30 years. The
incidence rate for women over 20 years of age was two cases per
1000 woman-years.
The incidence ofclinical cancer before the start of the screening
in Denmark and Maribo County increases steeply at a young age
and decreases after age 50 (Table 4). The incidence of clinical
cancer for women between 30 and 60 years ofage was between 0.4
and 0.9 per 1000 woman-years, and the highest incidence was
found for women in their forties. Incidence ofclinical cancer is esti-
mated for women at risk (with a cervix uteri) in Maribo County.
Regression and non-progression of preclinical lesions
The estimated interval regression for women 25-50 years of age is
shown in Table 5. The prevalence at age 25 was 10.3 per 1000
Table 4 Incidence of clinical cervical cancer in Denmark and in Maribo
County, 1958-62, and estimated incidence of clinical cervical cancer (/c) for
women at rsk in Maribo County
Age Maribo County 1958-62 Denmark 1958-62 IC
Rates Cases Rates Cases Rates
(10-5 (10- (10-5 years
years) years)a at risk)b
< 20 0.0 (0) 0.1 ( 1) 0.1
20-24 0.0 ( 0) 2.0 (15) 2.0
25-29 17.3 ( 3) 15.9 (112) 16.0
30-34 41.1 ( 8) 42.1 (306) 42.8
35-39 87.3 (19) 75.3 (589) 77.8
40-44 65.5 (14) 85.1 (651) 90.4
45-49 111.9 (24) 85.8 (661) 94.5
50-54 98.6 (21) 76.7 (568) 86.7
55-59 83.3 (16) 69.4 (462) 79.5
60-64 55.3 (10) 58.6 (345) 67.7
65-69 19.4 ( 3) 52.6 (252) 61.1
70-74 57.5 ( 7) 39.0 (145) 45.5
75-79 35.7 ( 3) 36.8 ( 93) 43.1
80+ 69.4 ( 5) 41.6 ( 84) 49.0
aincidence of clinical cancer rates in Denmark (Doll et al, 1995).
bCalculated from incidence of clinical cancer in Denmark and hysterectomy
rates from Maribo County.
women (from Table 2), the cumulative incidence of preclinical
lesion over the age 25 to 50 was 57.7 per 1000 woman-years (from
Table 3). The prevalence at age 50 was 25.5 per 1000 women (from
Table 2) and the cumulative incidence ofclinical cancer of women
between 25 and 50 years of age was 16.1 per 1000 woman-years
(from Table 4). The estimated proportion of lesions that regressed
during the interval (interval regression) was therefore [(10.3 +
57.7) - (25.5 + 16.1)]/(10.3 + 57.7) = 0.39 or 39%. The interval
progression was 16.1/(10.3 + 57.7) = 0.24 or 24%, and at age 50,
38% [25.5/(10.3 + 57.7)] ofall lesions was still prevalent.
The cumulative incidence in women aged 50-80 is 19.2 per
1000 woman-years (from Table 4). If we assume that there is no
progressive onset ofpreclinical lesions after age 50, the proportion
ofprevalent preclinical lesions at age 50 that will progress to clin-
ical cancer can be estimated to be 19.2/25.5 = 0.75 or 75%. The
minimal non-progression is then 0.39 + 0.38 x 0.25 = 0.48 or48%
(see Table 5). This is a minimum, as we assume no onset of
preclinical lesions after age 50 and survival to age 80.
For the estimations above we used a sensitivity of 80%. Table 5
also shows calculations for a sensitivity of 70%, 80% and 90%.
The impact of the different assumptions about sensitivity on the
estimates is small. For a sensitivity of70%, 80% and 90%, respec-
tively, the estimated interval regression before age 50 years is
0.35, 0.39 and 0.42 and the non-progression rate for lesions in
women aged 25-50 is, respectively, 0.47, 0.48 and 0.49.
Figure 2, for women at risk and ifno screening had taken place,
shows the relation between the probabilities ofhaving developed a
preclinical lesion (= incidence of preclinical lesions), of having
developed a clinical cervical cancer (= incidence of clinical
cancer) and of having a preclinical lesion (= prevalence). At a
young age the proportion ofregression and progression was small,
due to the average long duration of preclinical lesions. The fact
that the regression widens more than linearly with age suggests
that interval regression increased with age. Between age 45 and 55
the probability ofregression increases considerably.
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Table 5 Estimation of proportion regressed, progressed and prevalent lesions for women 25-50 years of age (and confidence intervals of the estimations)
Sensitivity (%) PI Id P2 I. Missing Interval Interval Prevalent Non-progression
(X) regression progression at age 50 after age 25
80 10.3 57.7 25.5 16.1 26.3 0.39 0.24 0.38 0.48
(0.25-0.50) (0.20-0.27) (0.28-0.50) (0.39-0.56)
70 11.7 57.7 29.1 16.1 24.2 0.35 0.23 0.42 0.49
(0.19-0.47) (0.20-0.27) (0.32-0.56) (0.40-0.57)
90 9.1 57.7 22.7 16.1 28.0 0.42 0.24 0.34 0.47
(0.29-0.53) (0.21-0.28) (0.25-0.45) (0.38-0.55);
Pl, prevalence at age 25 (per 1000 women); /d' incidence preclinical lesions (per 1000 woman-years) between ages 25 and 50; P2, prevalence at age 50 (per 1000
women); /c, incidence clinical cancer (per 1000 women) between age 25 and 50. Missing (X), (P, + /d) - (P2 + /C); interval regression, [(P1 + /d) - (P2 + IC)]/(Pl + id);
interval progression, I,/(P1 + /d); prevalent lesions at age 50, P/(P, + Id). Non-progression after age 25 = interval regression + prevalent at age 50 x non-
progression after age 50 (= /c, women 50-80, IP2).
Table 6 Estimated mean duration m and shape b of the Weibull distribution
function of the preclinical duration (and confidence interval)
Sensitivity Mean duration Shape
(%) m (years) b
70 17.6 5.8
(14.8-23.8) (2.0-c)
80 15.7 3.2
(13.4-24.6) (1.2-c')
90 14.2 2.0
(10.0-181.9) (0.3--c)
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Figure 2 The probability of developing a preclinical cervical lesion, and
probabilities of prevalence, progression and regression, under the assumption
that there is no onset of preclinical lesions in women over 50 years of age.
The preclinical incidence is the prevalence (from Table 2) at age 25 + the
cumulative incidence of preclinical cervical lesions (from Table 3) in women
after age 25. The cumulative incidence of preclinical cervical lesions
(/d fromTable 3) is converted into probabilities using the formula: P = 1 - exp
(-r.d). The clinical incidence in this figure is the cumulative incidence of
clinical cervical cancer (/c from Table 4).
In the estimation ofnon-progression we assumed that all women
survive up to age 80. However, a proportion of women with
progressive lesions will die from other causes before the cancer is
diagnosed clinically. After correction for mortality [using 1993
mortality rates (Danmarks Statistik, 1993)], the cumulative inci-
dence ofclinical cancer for women aged 50-80 years will be 17.0.
The proportion of lesions which progress after age 50 will be
17.0/25.5 = 0.66 or 66%. Under these assumptions, the minimal
non-progression is 0.39 + 0.38 x 0.34 = 0.51 or 51%.
Duration of the preclinical lesion
For a sensitivity of70%, 80% and 90%, respectively, we estimated
the mean duration of the preclinical lesion to be 17.6, 15.7 and
14.2 years, respectively (Table 6). The estimated duration is only
marginally influenced by the sensitivity.
DISCUSSION
The natural history of the detectable preclinical phase of cervical
cancer can only be studied indirectly on the basis of screening
data. We estimated non-progression and duration from the Maribo
County data using a two-step procedure. Firstly, the prevalence
and incidence rates ofpreclinical disease were estimated from the
observed detection rates. Secondly, the non-progression and dura-
tion were assessed, also using the prescreening incidence of clin-
ical cancer as a proxy for the expected incidence if no screening
had taken place. The main findings were that at least 48% of the
lesions in women between 25 and 50 years of age do not progress
into.clinical cancer. If one accounts for death from causes other
than cervical cancer, this minimum percentage increases to around
51%. The mean duration of all preclinical lesions was estimated
at 16 years.
Our estimate for non-progression is based on detected lesions.
Short regressive lesions would have stayed undetected if they
developed and regressed within a screening interval. This causes
an underestimation ofthe proportion ofnon-progression. The side-
effects associated with the detection of non-progressive lesions
howNever, are not underestimated.
The estimation procedure for regression and non-progression
was performed under the assumption that there is no cohort effect
in the observed period. In an age-period-cohort analysis of inci-
dence of clinical cancer in Denmark before 1967, we found that
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women born in the years 1918-29 were presumably at higher risk
than women born later. If such a cohort effect occurred, the preva-
lence at age 50 and the incidence of clinical cancer were overesti-
mated, leading to an underestimation of the non-progressive rate.
Such a cohort effect would also lead to a decrease in detection
rates with ascending calendar years. However we found that the
detection rates for 1975-82 were in fact higher than the rates ofthe
period 1966-74. This cannot be explained by an increase in inci-
dence of cervical cancer at a young age, because such an increase
was only modest in Denmark and seen only after 1983.
Furthermore, the increase in detection rates was seen in all age
groups. An explanation for this observation could be a drift over
time towards a lower 'follow-up threshold' and in consequence, a
higher sensitivity at the expense of specificity.
We used the incidence of invasive cervical cancer before the
screening programme started, to estimate the incidence of clinical
cancer in the screened women if no screening had taken place. For
participants however, the incidence of cervical cancer has been
found to be relatively low (Berget, 1979; Magnus et al 1987;
Oortmarssen and Habbema, 1991). Not accounting for this lower
incidence leads to an underestimation of the non-progression.
Assuming an incidence level in participants of 74% of the total
population (Oortmarssen and Habbema, 1991), the minimal non-
progression fraction would increase from 48% to 54%, or from 51%
to 58% ifone accounts for death from other causes.
Using prevalence and incidence of preclinical lesions and inci-
dence of clinical cancer from British Columbia, Canada in
1949-69 (Boyes et al, 1982), we estimated that 48% of the lesions
in women between 25 and 50 years ofage regressed before the age
of 50, which is somewhat higher than the 39% found in Maribo
County. Gustafsson et al (1989) analysed Swedish screening data
and estimated the progression rate for carcinoma in situ at 12%,
which is considerably lower than the maximum proportion of
progression for all preclinical lesions of 52% found for Maribo
County. At least part of the difference is explained by the fact that
the Swedish study included onset of preclinical lesions also after
the age of 50. Hence, a smaller proportion of the clinical cancer
after age 50 is explained by the preclinical cancer developed
before this age.
The estimated mean duration of the preclinical lesions in
Maribo County was 16 years, compared with 15.8 years in British
Columbia (Oortmarssen and Habbema, 1991) and 17.3 years in
Sweden (Gustafsson and Adami, 1989). These estimates are
remarkably similar, despite differences in calculation methods and
between the screening programmes. These estimates of duration
represent an average for the regressive, stable and progressive
lesions. They may well have different mean durations, but it is not
possible to separate these using this rather straightforward
analysis. For the purpose of screening it is the duration of progres-
sive lesions that is important. Van Oortmarssen et al (1995)
showed that an average duration of 15.8 years for preclinical
progressive disease is compatible with the interval cancer data
collected by the IARC in the eighties, which also involved data
derived from the Maribo County data set studied in this paper
(IARC, 1986; Lynge and Poll, 1986b).
Our study confirmed that non-progression is a common phenom-
enon that should be taken into account in the evaluation ofcervical
cancer screening. Of the screened women in Maribo County, 1.5%
had a positive smear with at least atypia, and the majority of these
women were followed up: one-third with a negative diagnosis and
two-thirds with a histologically confirmed preclinical lesion. Our
analysis shows that at least half of these confirmed preclinical
lesions would not have progressed into clinical cancer in the
women's lifetime. Thus, among the women screened in Maribo
County, 5 per 1000 were diagnosed with a false-positive smear, 5
per 1000 were diagnosed and treated for a non-progressive pre-
clinical lesion, and 5 per 1000 were diagnosed and treated for a
preclinical lesion that would otherwise have developed into inva-
sive cervical cancer. The screened women thus pay a price in
overtreatment in order to minimize the incidence and mortality
from cervical cancer. But given the severity of the disease and the
relatively mild treatment with conization, cryotherapy and laser
therapy, this price - as it is estimated for Maribo County in the
period studied - seems reasonable.
Analysis of data from the cervical cancer screening programme
in Bristol (Raffle et al, 1995) in the years 1988-93, showed that
7% of the screened women had smear abnormalities, and 2.7%
were referred to colposcopy. This latter proportion is close to
double that for Maribo County, which is high, taking into account
that incidence of invasive cancer was, and still is, appreciably
higher in Denmark than in the UK (37 per 100 000 in Denmark in
1958-62 (Doll et al, 1966) and 17 per 100 000 in England and
Wales in 1960-62 (Doll et al, 1970); 16 per 100 000 in Denmark
and 12 per 100 000 in England and Wales in 1983-87 (Parkin et al,
1992). The cervical cancer screening data from the Netherlands
from 1987 to 1990 show more than 10% positive smears (PALGA,
1992). Similarly, up to 10% of cervical smears from the United
States currently have ASCUS or more severe abnormalities
(Singer, 1995) and 5% of all smears have low-grade squamous
intraepithelial lesions (Kurman et al, 1994).
It is clear that there is a considerable variation in the cost in
terms of overtreatment paid by different populations to prevent
progressive preclinical lesions. It is therefore worrying that over
recent decades, there has been a tendency in several countries to
advise more intensive follow-up after slightly abnormal Pap
smears. Owing to the estimated long duration in combination with
a relatively high sensitivity for the preclinical lesion, the extra
incidence and mortality reduction from more intense follow-up of
slightly abnormal Pap smears in regular attenders, to a 3-5 yearly
screening, is expected to be very low.
ABBREVIATIONS
CIN, cervical intraepithelial neoplasia; ASCUS, atypical squa-
mous cells ofundetermined significance.
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